PCAS: 2017 Annual Results
February 20 2018 - 12:00PM
2017 ANNUAL
RESULTS
Longjumeau,
February 20, 2018
PCAS (Euronext
Paris: PCA), specialists in the development and generation of
complex molecules for life sciences and innovative technologies,
publishes its annual income statement for 2017.
in millions of euros |
|
2016 |
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
Chiffre d'affaires |
|
192,0 |
|
218,3 |
|
EBITDA (*) |
|
27,3 |
|
31,5 |
|
|
EBITDA margin |
|
14,2% |
|
14,4% |
|
|
|
|
|
|
|
|
Current operating income (*) |
|
16,2 |
|
19,1 |
|
|
Current operating income margin |
|
8,4% |
|
8,8% |
|
|
|
|
|
|
|
|
Other operating income and expenses |
|
-2,3 |
|
-5,2 |
|
|
|
|
|
|
|
|
Operating income |
|
13,9 |
|
13,9 |
|
|
|
|
|
|
|
|
Financial result |
|
-6,4 |
|
-4,4 |
|
Taxes |
|
-0,9 |
|
-3,8 |
|
|
|
|
|
|
|
|
Net result |
|
6,6 |
|
5,8 |
|
(*) of which research tax credit (CIR):
3.3 M€ in 2016 and 3.7 M€ in 2017 |
|
|
Audit procedures have been performed and
auditor's report is in progress of being issued. |
Earnings
At December 31, 2017, consolidated net sales
for the PCAS Group totaled €218.3 million, up
13.7% compared to the same period for the previous year.
EBITDA
totaled €31.5 million, against
€27.3 million in 2016, a margin of 14.4%
against 14.2% in 2016. The Group's current
operating income totaled €19.1 million,
against €16.2 million in 2016, boosted by the growth in Group
activities.
The financial
result totaled -€4.4 million in 2017,
against -€6.4 million in 2016.
PCAS Group's net
income totaled €5.8 million in 2017,
against €6.6 million in 2016.
The Group's net
debt stood at €56.7 million against
€48.7 million at December 31, 2016, affected by an increase in
accounts receivable due to a sharp rise in sales at the end of
2017, and to a lesser extent by higher inventory levels than at the
end of the previous year.
Outlook for the current
year
In 2018 the Group's net sales are expected to show modest growth.
The Group's net income could however be significantly affected if
the current euro-dollar rate were to be confirmed.
Dividend
Given an ambitious investment program to support the business
growth, the Board of Directors will ask the next Annual General
Meeting not to approve payment of a dividend on the earnings of
2017.
|
NEXT
FINANCIAL DISCLOSURE: |
2018
Shareholder's Meeting in Longjumeau at 10 a.m. on April 25,
2018 |
ABOUT PCAS
PCAS specializes in the development and production of complex
molecules for life sciences and innovative technologies. With 7% of
its net sales earmarked for R&D and a large international
footprint, PCAS is the preferred industrial partner for
market-leading major global groups. Boasting especially high
standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €218.3 million in 2017 and employs close to 1 100 people
in six countries.
To find out more about PCAS,
visit: www.pcas.com
PCAS |
NewCap |
Vincent Touraille / Eric
Moissenot
PCAS |
Emmanuel Huynh / Louis-Victor
Delouvrier
Financial communication and Investor Relations |
Tel. : +33 1 69 79 61 32
www.pcas.com
|
Tel. : +33 1 44 71 98 53
pcas@newcap.eu |
pcas_2017_FYR
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: PCAS via Globenewswire
PCAS (EU:PCA)
Historical Stock Chart
From Mar 2024 to Apr 2024
PCAS (EU:PCA)
Historical Stock Chart
From Apr 2023 to Apr 2024